3D bioprinting technology provides platforms for drug discovery and drug development, as the tissues developed through this technology help in improving drug efficacy. Additionally, the adoption of 3D bioprinting also helps in reducing the time taken for clinical trials. In recent years, the surging number of collaborations between 3D bioprinting and pharmaceutical companies for drug testing at the initial stage of clinical development, have amplified the usage of this technology worldwide. Moreover, the escalating focus of pharmaceutical companies on developing new drugs from 3D printed tissues will fuel the usage of this technology in the coming years.
Additionally, the growing stem cell research will also create a huge requirement for 3D bioprinters in the coming years. Owing to the widening application base of this printing technology, Organovo Holdings Inc., 3D Bioprinting Solutions, 3Dynamic Systems Ltd., CELLINK, Ourobotics, Nano3D Biosciences Inc., EnvisionTEC, Advanced Solutions Inc., Poietis, BioBots, Advanced Solutions Inc., regenHU Ltd., Cyfuse Biomedical K.K., GeSiM GmbH, Aerotech Inc., Aspect Biosystems Ltd., and Bio3D Technologies are manufacturing such bioprinters in abundance.
3D bioprinters offered by the aforementioned companies are based on syringe, laser, inkjet, and pneumatic extrusion technologies. At present, pharmaceutical companies, laboratories, and academic institutes are preferring syringe-based 3D bioprinters over others. Whereas, in the coming years, these end-users will adopt pneumatic extrusion-based 3D bioprinters at the highest rate, due to the high-resolution quality offered by the technology. In the coming years, these bioprinters will be adopted by the cosmetic industry at the highest rate, as they help in the construction of skin tissues.
The aforementioned 3D bioprinters are used for tissue and organ regeneration, drug discovery, and 3D cell culture applications. Nowadays, these printers are being widely used for tissue and organ regeneration, owing to the burgeoning demand for organ implants. The escalating need for organ implants can be attributed to the rising prevalence of chronic and lifestyle associated diseases and road accidents. Whereas, in the coming years, such bioprinters will be widely used for 3D cell culture, due to the extensive research being carried out in the field of stem cells.
According to P&S Intelligence, North America will dominate the 3D bioprinting market in the foreseeable future, due to the rising technological advancements and surging R&D activities in the region. Moreover, the presence of a highly developed healthcare infrastructure and prominent 3D bioprinter manufacturers in the region augments the use of such printing technology in North America. Additionally, the booming population of the elderly and the growing prevalence of chronic diseases will also fuel the adoption of 3D bioprinting technology in the region in the coming years.
Thus, the mounting focus of pharmaceutical firms on drug discovery and drug development and increasing R&D activities being conducted to reduce the cost of 3D bioprinters will boost the adoption of 3D bioprinting technology in the coming years.